Literature DB >> 19056775

Assessing long-run economic benefits attributed to an IVF-conceived singleton based on projected lifetime net tax contributions in the UK.

M Connolly1, F Gallo, S Hoorens, W Ledger.   

Abstract

BACKGROUND: Over the past decade, demand for fertility treatments has increased as a result of delaying time to first pregnancy and growing awareness and acceptance of available treatment options. Despite increasing demand, health authorities often view infertility as a low health priority and consequently limit access to treatments by rationing and limiting funds.
METHODS: To assess the long-term economic benefits attributed to in vitro fertilization (IVF)-conceived children, we developed a health investment model to evaluate whether state-funded IVF programmes in the UK represent sound fiscal policies. Based on the average investment cost to conceive an IVF singleton, we describe the present value of net taxes derived from gross taxes paid minus direct government transfers received (e.g. education, health, pension) over the lifetime of the child. To establish the present value of investing in IVF, we have discounted all costs from benefits (i.e. lifetime taxes paid) using UK Treasury department rates based on a singleton delivery with similar characteristics for education, earnings, health and life expectancy to a naturally conceived child.
RESULTS: The lifetime discounted value of net taxes from an IVF-conceived child with mother aged 35 is pound 109,939 compared with pound 122,127 for a naturally conceived child. The lifetime undiscounted net tax contribution for the IVF-conceived child and naturally conceived child are pound 603,000 and pound 616,000, respectively.
CONCLUSIONS: An investment of pound 12,931 to achieve an IVF singleton is actually worth 8.5-times this amount to the UK Treasury in discounted future tax revenue. The analysis underscores that costs to the health sector are actually investments when a broader government perspective is considered over a longer period of time.

Entities:  

Mesh:

Year:  2008        PMID: 19056775     DOI: 10.1093/humrep/den435

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

1.  Double trouble: should double embryo transfer be banned?

Authors:  Dominic Wilkinson; G Owen Schaefer; Kelton Tremellen; Julian Savulescu
Journal:  Theor Med Bioeth       Date:  2015-04

2.  A reduction in public funding for fertility treatment--an econometric analysis of access to treatment and savings to government.

Authors:  Georgina M Chambers; Van Phuong Hoang; Rong Zhu; Peter J Illingworth
Journal:  BMC Health Serv Res       Date:  2012-06-08       Impact factor: 2.655

3.  Economic value of in vitro fertilization in Ukraine, Belarus, and Kazakhstan.

Authors:  Olena Mandrik; Saskia Knies; Johan L Severens
Journal:  Clinicoecon Outcomes Res       Date:  2015-06-12

4.  Is mandating elective single embryo transfer ethically justifiable in young women?

Authors:  Kelton Tremellen; Dominic Wilkinson; Julian Savulescu
Journal:  Reprod Biomed Soc Online       Date:  2016-02-18

5.  Long-term fiscal implications of funding assisted reproduction: a generational accounting model for Spain.

Authors:  R Matorras; R Villoro; A González-Domínguez; S Pérez-Camarero; A Hidalgo-Vega; C Polanco
Journal:  Reprod Biomed Soc Online       Date:  2016-05-13

6.  Estimating the government public economic benefits attributed to investing in assisted reproductive technology: a South African case study.

Authors:  Mark P Connolly; Saswat Panda; Gitau Mburu; Thabo Matsaseng; James Kiarie
Journal:  Reprod Biomed Soc Online       Date:  2020-09-04

7.  The Lack of Ireland's Assisted Human Reproduction (AHR) Regulation Viewed under the Lens of the Patient's Experience.

Authors:  Lauraine Ronan; Olivia McDermott; Mary Butler; Anna Trubetskaya
Journal:  Int J Environ Res Public Health       Date:  2022-08-03       Impact factor: 4.614

8.  Estimating the long-term effects of in vitro fertilization in Greece: an analysis based on a lifetime-investment model.

Authors:  Vassilis Fragoulakis; Nikolaos Maniadakis
Journal:  Clinicoecon Outcomes Res       Date:  2013-06-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.